204 related articles for article (PubMed ID: 22022351)
1. Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness.
Tseng YF; Hu AY; Huang ML; Yeh WZ; Weng TC; Chen YS; Chong P; Lee MS
PLoS One; 2011; 6(10):e24057. PubMed ID: 22022351
[TBL] [Abstract][Full Text] [Related]
2. A Vero-cell-adapted vaccine donor strain of influenza A virus generated by serial passages.
Hu W; Zhang H; Han Q; Li L; Chen Y; Xia N; Chen Z; Shu Y; Xu K; Sun B
Vaccine; 2015 Jan; 33(2):374-81. PubMed ID: 25448099
[TBL] [Abstract][Full Text] [Related]
3. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production.
Dong J; Matsuoka Y; Maines TR; Swayne DE; O'Neill E; Davis CT; Van-Hoven N; Balish A; Yu HJ; Katz JM; Klimov A; Cox N; Li DX; Wang Y; Guo YJ; Yang WZ; Donis RO; Shu YL
Influenza Other Respir Viruses; 2009 Nov; 3(6):287-95. PubMed ID: 19903211
[TBL] [Abstract][Full Text] [Related]
4. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1.
Zhou F; Zhou J; Ma L; Song S; Zhang X; Li W; Jiang S; Wang Y; Liao G
Biochem Biophys Res Commun; 2012 May; 421(4):850-4. PubMed ID: 22554519
[TBL] [Abstract][Full Text] [Related]
5. Cell-cultured, live attenuated, X-31ca-based H5N1 pre-pandemic influenza vaccine.
Lee YH; Jang YH; Seong BL
Virology; 2017 Apr; 504():73-78. PubMed ID: 28157547
[TBL] [Abstract][Full Text] [Related]
6. Preparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells.
Legastelois I; Garcia-Sastre A; Palese P; Tumpey TM; Maines TR; Katz JM; Vogel FR; Moste C
Influenza Other Respir Viruses; 2007 May; 1(3):95-104. PubMed ID: 19453414
[TBL] [Abstract][Full Text] [Related]
7. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
[TBL] [Abstract][Full Text] [Related]
8. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.
Mayrhofer J; Coulibaly S; Hessel A; Holzer GW; Schwendinger M; Brühl P; Gerencer M; Crowe BA; Shuo S; Hong W; Tan YJ; Dietrich B; Sabarth N; Savidis-Dacho H; Kistner O; Barrett PN; Falkner FG
J Virol; 2009 May; 83(10):5192-203. PubMed ID: 19279103
[TBL] [Abstract][Full Text] [Related]
9. A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®].
Plosker GL
Drugs; 2012 Jul; 72(11):1543-57. PubMed ID: 22788239
[TBL] [Abstract][Full Text] [Related]
10. Permissible variation in the 3' non-coding region of the haemagglutinin genome segment of the H5N1 candidate influenza vaccine virus NIBRG-14 [corrected].
Johnson RE; Hamill M; Harvey R; Nicolson C; Robertson JS; Engelhardt OG
PLoS One; 2012; 7(5):e36241. PubMed ID: 22606247
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of novel disposable bioreactors on pandemic influenza virus production.
Lai CC; Weng TC; Tseng YF; Chiang JR; Lee MS; Hu AY
PLoS One; 2019; 14(8):e0220803. PubMed ID: 31404117
[TBL] [Abstract][Full Text] [Related]
12. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.
Pandey A; Singh N; Sambhara S; Mittal SK
Hum Vaccin; 2010 Feb; 6(2):178-88. PubMed ID: 19875936
[TBL] [Abstract][Full Text] [Related]
13. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.
Brewoo JN; Powell TD; Jones JC; Gundlach NA; Young GR; Chu H; Das SC; Partidos CD; Stinchcomb DT; Osorio JE
Vaccine; 2013 Apr; 31(14):1848-55. PubMed ID: 23376279
[TBL] [Abstract][Full Text] [Related]
14. Production of adenovirus vectors and their use as a delivery system for influenza vaccines.
Vemula SV; Mittal SK
Expert Opin Biol Ther; 2010 Oct; 10(10):1469-87. PubMed ID: 20822477
[TBL] [Abstract][Full Text] [Related]
15. Cloned cDNA of A/swine/Iowa/15/1930 internal genes as a candidate backbone for reverse genetics vaccine against influenza A viruses.
Lekcharoensuk P; Wiriyarat W; Petcharat N; Lekcharoensuk C; Auewarakul P; Richt JA
Vaccine; 2012 Feb; 30(8):1453-9. PubMed ID: 22230579
[TBL] [Abstract][Full Text] [Related]
16. Establishment of Vero cell RNA polymerase I-driven reverse genetics for Influenza A virus and its application for pandemic (H1N1) 2009 influenza virus vaccine production.
Song MS; Baek YH; Pascua PNQ; Kwon HI; Park SJ; Kim EH; Lim GJ; Choi YK
J Gen Virol; 2013 Jun; 94(Pt 6):1230-1235. PubMed ID: 23486669
[TBL] [Abstract][Full Text] [Related]
17. Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment.
Yu W; Yang F; Yang J; Ma L; Cun Y; Song S; Liao G
J Med Virol; 2016 Nov; 88(11):1914-21. PubMed ID: 27101353
[TBL] [Abstract][Full Text] [Related]
18. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
[TBL] [Abstract][Full Text] [Related]
19. Generation of a High-Growth Influenza Vaccine Strain in MDCK Cells for Vaccine Preparedness.
Kim EH; Kwon HI; Park SJ; Kim YI; Si YJ; Lee IW; Kim SM; Kim SI; Ahn DH; Choi YK
J Microbiol Biotechnol; 2018 Jun; 28(6):997-1006. PubMed ID: 29642288
[TBL] [Abstract][Full Text] [Related]
20. Strategies for developing vaccines against H5N1 influenza A viruses.
Horimoto T; Kawaoka Y
Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
